Morgan Stanley Crinetics Pharmaceuticals, Inc. Transaction History

Morgan Stanley

$1.35 Trillion
Q3 2024

A detailed history of Morgan Stanley transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Morgan Stanley holds 665,599 shares of CRNX stock, worth $36.4 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

665,599

Previous 838,625 20.63%

Holding current value

$36.4 Million

Previous $37.6 Million 9.49%

% of portfolio

0.0%

Previous 0.0%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$43.83 - $54.98 $7.58 Million - $9.51 Million	-173,026 Reduced 20.63%	665,599 $34 Million
Q2 2024 Oct 17, 2024	BUY	$42.12 - $51.91 $9.54 Million - $11.8 Million	226,425 Added 36.99%	838,625 $37.6 Million
Q2 2024 Aug 14, 2024	BUY	$42.12 - $51.91 $9.54 Million - $11.8 Million	226,425 Added 36.99%	838,625 $37.6 Million
Q1 2024 Oct 17, 2024	SELL	$34.76 - $46.81 $7.87 Million - $10.6 Million	-226,425 Reduced 27.0%	612,200 $28.7 Million
Q1 2024 Aug 16, 2024	SELL	$34.76 - $46.81 $1.25 Million - $1.69 Million	-36,051 Reduced 5.56%	612,200 $28.7 Million
Q1 2024 May 15, 2024	SELL	$34.76 - $46.81 $1.25 Million - $1.69 Million	-36,051 Reduced 5.56%	612,200 $28.7 Million
Q4 2023 Aug 16, 2024	SELL	$25.62 - $37.07 $4.88 Million - $7.06 Million	-190,374 Reduced 22.7%	648,251 $23.1 Million
Q4 2023 Feb 13, 2024	BUY	$25.62 - $37.07 $3.51 Million - $5.08 Million	136,930 Added 26.78%	648,251 $23.1 Million
Q3 2023 Nov 15, 2023	SELL	$15.97 - $30.59 $3.75 Million - $7.18 Million	-234,838 Reduced 31.47%	511,321 $15.2 Million
Q2 2023 Aug 14, 2023	BUY	$15.73 - $23.6 $1.47 Million - $2.2 Million	93,243 Added 14.28%	746,159 $13.4 Million
Q1 2023 May 15, 2023	BUY	$15.31 - $21.1 $7.66 Million - $10.6 Million	500,328 Added 327.89%	652,916 $10.5 Million
Q4 2022 Feb 14, 2023	BUY	$15.49 - $19.05 $783,112 - $963,091	50,556 Added 49.55%	152,588 $2.79 Million
Q3 2022 Nov 14, 2022	SELL	$18.11 - $22.37 $680,646 - $840,754	-37,584 Reduced 26.92%	102,032 $2 Million
Q2 2022 Oct 27, 2022	BUY	$16.49 - $27.64 $730,935 - $1.23 Million	44,326 Added 46.52%	139,616 $2.61 Million
Q2 2022 Aug 15, 2022	BUY	$16.49 - $27.64 $730,935 - $1.23 Million	44,326 Added 46.52%	139,616 $2.61 Million
Q1 2022 Oct 27, 2022	SELL	$17.15 - $28.31 $760,190 - $1.25 Million	-44,326 Reduced 31.75%	95,290 $2.09 Million
Q1 2022 May 13, 2022	BUY	$17.15 - $28.31 $982,900 - $1.62 Million	57,312 Added 150.91%	95,290 $2.09 Million
Q4 2021 Feb 14, 2022	SELL	$19.35 - $28.41 $599,385 - $880,028	-30,976 Reduced 44.92%	37,978 $1.08 Million
Q3 2021 Nov 15, 2021	BUY	$16.88 - $25.23 $1.16 Million - $1.74 Million	68,954 New	68,954 $1.45 Million

Others Institutions Holding CRNX

# of Institutions

240

Shares Held

79.5M

Call Options Held

23.3K

Put Options Held

44.3K

View Full List

About Crinetics Pharmaceuticals, Inc.

Ticker CRNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,752,800
Market Cap $2.94B
Description
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...

More about CRNX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account